Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16. No abstract available.

2.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

3.

Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals.

Score J, Chase A, Forsberg LA, Feng L, Waghorn K, Jones AV, Rasi C, Linch DC, Dumanski JP, Gale RE, Cross NC.

Leukemia. 2015 Jul;29(7):1600-2. doi: 10.1038/leu.2015.13. Epub 2015 Jan 28. No abstract available.

PMID:
25627638
4.

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.

Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A.

Ann Hematol. 2015 Feb;94(2):233-8. doi: 10.1007/s00277-014-2221-y. Epub 2014 Sep 27.

PMID:
25260694
5.

Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.

Winkelmann N, Hidalgo-Curtis C, Waghorn K, Score J, Dickinson H, Jack A, Ali S, Cross NC.

Leuk Lymphoma. 2013 Jul;54(7):1527-31. doi: 10.3109/10428194.2012.753544. Epub 2013 Jan 28.

PMID:
23186533
6.

The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia.

Grand FH, Waghorn K, Ernst T, Ohyashiki K, Cross NC.

Leukemia. 2011 Jun;25(6):1049-50. doi: 10.1038/leu.2011.40. Epub 2011 Mar 15. No abstract available.

PMID:
21403647
7.

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC.

Nat Genet. 2010 Aug;42(8):722-6. doi: 10.1038/ng.621. Epub 2010 Jul 4.

PMID:
20601953
8.

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.

Ernst T, Chase A, Zoi K, Waghorn K, Hidalgo-Curtis C, Score J, Jones A, Grand F, Reiter A, Hochhaus A, Cross NC.

Haematologica. 2010 Sep;95(9):1473-80. doi: 10.3324/haematol.2010.021808. Epub 2010 Apr 26.

9.

A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.

Kreil S, Waghorn K, Ernst T, Chase A, White H, Hehlmann R, Reiter A, Hochhaus A, Cross NC; German CML Study Group.

Haematologica. 2010 Jan;95(1):148-52. doi: 10.3324/haematol.2009.011510.

10.

Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder.

Townsend W, Cross NC, Waghorn K, Somana K, Ramsay A, Thomson K, Peggs K.

Bone Marrow Transplant. 2009 Aug;44(3):197-9. doi: 10.1038/bmt.2008.448. Epub 2009 Feb 23. No abstract available.

PMID:
19234514
11.

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions.

Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Curtis C, Lin F, Grimwade D, Grand F, Reiter A, Cross NC.

Leukemia. 2009 Feb;23(2):332-9. doi: 10.1038/leu.2008.309. Epub 2008 Nov 6.

PMID:
18987650
12.

The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.

Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, Zoi K, White H, Cilloni D, Zoi C, Brito-Babapulle F, Walz C, Reiter A, Cross NC.

Leukemia. 2007 Dec;21(12):2428-32. Epub 2007 Oct 4.

PMID:
17914408
13.

A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.

Curtis CE, Grand FH, Waghorn K, Sahoo TP, George J, Cross NC.

Leukemia. 2007 Aug;21(8):1839-41. Epub 2007 May 17. No abstract available.

PMID:
17508004
14.

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC; German Chronic Myelogenous Leukemia (CML) Study Group.

Blood. 2007 Aug 15;110(4):1283-90. Epub 2007 Apr 24.

15.

Continuity of nursing care and its link to cesarean birth rate.

Gagnon AJ, Meier KM, Waghorn K.

Birth. 2007 Mar;34(1):26-31.

PMID:
17324175
16.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.

Blood. 2007 Jun 1;109(11):4635-40. Epub 2007 Feb 13.

17.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z, Apperley JF.

Blood. 2007 Jan 1;109(1):61-4. Epub 2006 Sep 7.

18.

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.

Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC.

Leukemia. 2006 May;20(5):827-32.

PMID:
16498388
19.

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G, Lengfelder E, Reiter A, Chase AJ, Cross NC.

Blood. 2006 Apr 15;107(8):3339-41. Epub 2005 Dec 13.

20.

In-hospital formula supplementation of healthy breastfeeding newborns.

Gagnon AJ, Leduc G, Waghorn K, Yang H, Platt RW.

J Hum Lact. 2005 Nov;21(4):397-405.

PMID:
16280555
21.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC.

Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26.

22.

Indicators nurses employ in deciding to test for hyperbilirubinemia.

Gagnon AJ, Waghorn K, Jones MA, Yang H.

J Obstet Gynecol Neonatal Nurs. 2001 Nov-Dec;30(6):626-33.

PMID:
11724198
23.

One-to-one nurse labor support of nulliparous women stimulated with oxytocin.

Gagnon AJ, Waghorn K.

J Obstet Gynecol Neonatal Nurs. 1999 Jul-Aug;28(4):371-6.

PMID:
10438081
24.

A randomized trial of one-to-one nurse support of women in labor.

Gagnon AJ, Waghorn K, Covell C.

Birth. 1997 Jun;24(2):71-7.

PMID:
9271971
25.

A randomized trial of a program of early postpartum discharge with nurse visitation.

Gagnon AJ, Edgar L, Kramer MS, Papageorgiou A, Waghorn K, Klein MC.

Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):205-11.

PMID:
9024115
26.
27.

Relationship of episiotomy to perineal trauma and morbidity, sexual dysfunction, and pelvic floor relaxation.

Klein MC, Gauthier RJ, Robbins JM, Kaczorowski J, Jorgensen SH, Franco ED, Johnson B, Waghorn K, Gelfand MM, Guralnick MS, et al.

Am J Obstet Gynecol. 1994 Sep;171(3):591-8.

PMID:
8092203
28.

[Does episiotomy prevent perineal trauma and pelvic floor relaxation?].

Klein MC, Gauthier RJ, Jorgensen SH, Robbins JM, Kaczorowski J, Johnson B, Corriveau M, Westreich R, Waghorn K, Gelfand MM, et al.

Jordemodern. 1993 Oct;106(10):375-7. Swedish. No abstract available.

PMID:
8276683
29.

Does episiotomy prevent perineal trauma and pelvic floor relaxation?

Klein MC, Gauthier RJ, Jorgensen SH, Robbins JM, Kaczorowski J, Johnson B, Corriveau M, Westreich R, Waghorn K, Gelfand MM, et al.

Online J Curr Clin Trials. 1992 Jul 1;Doc No 10:[6019 words; 65 paragraphs]. Erratum in: Online J Curr Clin Trials 1992 Sep 12;Doc No 20:[54 words; 1.

PMID:
1343606

Supplemental Content

Loading ...
Support Center